A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FISH, HES/Leukemia, 4q12 Rearrangement (FIP1L1-PDGFRA)
MessageFor Specimen Integrity during Extreme Weather see the “Lockbox Usage in Extreme Weather” document at the top of this page.
Test Code
HES4Q
CPT Codes
88275, 88271 (x3)
Preferred Specimen
3 mL bone marrow or 5 mL whole blood collected in a sodium heparin (green-top) tube
Minimum Volume
1 mL bone marrow • 3 mL whole blood
Other Acceptable Specimens
Bone marrow or whole blood collected in: sodium heparin (royal blue-top) tube, or sodium heparin lead-free (tan-top) tube • 5x5mm fresh tumor tissue collected in transport medium or formalin-fixed paraffin-embedded tissue block
Instructions
Bone marrow: 1-3 mL in transport medium (preferred) or sodium heparin tube. 3-5 mL whole blood in sodium heparin tubes. Green, dark/ royal blue or tan top tubes are acceptable containers for this test. Formalin-fixed, paraffin-embedded block and fresh tumor tissue samples are also acceptable.
Note: 100-200 interphase nuclei are examined microscopically for the rearrangements of 4q12.
If results are not possible, the test order may be canceled and replaced with a Cytogenetics Communication.
Note: 100-200 interphase nuclei are examined microscopically for the rearrangements of 4q12.
If results are not possible, the test order may be canceled and replaced with a Cytogenetics Communication.
Transport Temperature
Room temperature
Specimen Stability
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Methodology
Fluorescence in situ Hybridization (FISH)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Sun-Fri; Report available: 5 days
Reference Range
See Laboratory Report
Clinical Significance
FIP1L1-PDGFRa fusion (rearrangement of 4q12; interstitial deletion of CHIC2 region) is observed in diverse eosinophilia-associated hematologic disorders. The cases with FIP1L1-PDGFRa fusion show an excellent response to the tyrosine kinase inhibitor imatinib mesylate (Metzgeroth et al, 2007)
Performing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20153
Last Updated: November 29, 2021